Literature DB >> 8220911

Human liver microsomal metabolism of the enantiomers of warfarin and acenocoumarol: P450 isozyme diversity determines the differences in their pharmacokinetics.

J J Hermans1, H H Thijssen.   

Abstract

1. To explain the large differences in (the stereoselectivity of) the clearances of the enantiomers of warfarin and acenocoumarol (4'-nitrowarfarin) their human liver microsomal metabolism has been studied and enzyme kinetic parameters determined. The effects of cimetidine, propafenone, sulphaphenazole, and omeprazole on their metabolism has been investigated. 2. The 4-hydroxycoumarins follow similar metabolic routes and are mainly hydroxylated at the 6- and 7-position (accounting for 63 to 99% of the metabolic clearances). 3. Due to the lower Km values of R- and S-acenocoumarol and higher Vmax values of S-acenocoumarol, the overall metabolic clearances of R/S acenocoumarol exceed those of R/S warfarin 6 and 66 times respectively. 4. The metabolism of both compounds is stereoselective for the S-enantiomers, which is 10 times more pronounced in the case of acenocoumarol. 5. Except for the 7-hydroxylation of the R-enantiomers (r = 0.90; P < 0.025), the 6- and 7-hydroxylation rates of R/S warfarin do not correlate with those of R/S acenocoumarol. 6. Sulphaphenazole competitively inhibits the 7- and in some samples partly (up to 50%) the 6-hydroxylation of S-warfarin as well as the 7-hydroxylation of R- and S-acenocoumarol and the 6-hydroxylation of S-acenocoumarol (Kis ranging from 0.5-1.3 microM). 7. Omeprazole partly (40-80%) inhibits the 6- and 7-hydroxylation of R-warfarin (Ki = 99 and 117 microM) and of R- (Ki = 219 and 7.2 microM) and S-acenocoumarol (Ki = 6.1 and 7.7 microM) but not S-warfarin in a competitive manner. 8. Differences in the partial (up to 40%) inhibition of the metabolism of the enantiomers of the 4-hydroxycoumarins were also observed for the relatively weak inhibitors, propafenone and cimetidine.9. The results suggest that the coumarin ring hydroxylations of both compounds are catalysed by different combinations of P450 isozymes. The 7-hydroxylation of R/S acenocoumarol and the 6-hydroxylation of S-acenocoumarol are at least partly conducted by (a) P450 isozyme(s) of the 2C subfamily different from P450 2C9 (the main S-warfarin 7- and 6-hydroxylase).

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8220911      PMCID: PMC2175972          DOI: 10.1111/j.1476-5381.1993.tb13836.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  37 in total

1.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

2.  Post mortem characteristics of the hepatic microsomal drug oxidising enzyme system.

Authors:  S M Macleod; K W Renton; N R Eade
Journal:  Chem Biol Interact       Date:  1973-07       Impact factor: 5.192

Review 3.  Purification and characterization of microsomal cytochrome P-450s.

Authors:  F P Guengerich; G A Dannan; S T Wright; M V Martin; L S Kaminsky
Journal:  Xenobiotica       Date:  1982-11       Impact factor: 1.908

4.  Stereoselective interaction of trimethoprim-sulfamethoxazole with the separated enantiomorphs of racemic warfarin in man.

Authors:  R A O'Reilly
Journal:  N Engl J Med       Date:  1980-01-03       Impact factor: 91.245

5.  An improved assay of 7-ethoxycoumarin O-deethylase activity: induction of hepatic enzyme activity in C57BL/6J and DBA/2J mice by phenobarbital, 3-methylcholanthrene and 2,3,7,8-tetrachlorodibenzo-p-dioxin.

Authors:  W F Greenlee; A Poland
Journal:  J Pharmacol Exp Ther       Date:  1978-06       Impact factor: 4.030

6.  Warfarin. Stereochemical aspects of its metabolism and the interaction with phenylbutazone.

Authors:  R J Lewis; W F Trager; K K Chan; A Breckenridge; M Orme; M Roland; W Schary
Journal:  J Clin Invest       Date:  1974-06       Impact factor: 14.808

7.  Purification and characterization of six cytochrome P-450 isozymes from human liver microsomes.

Authors:  P P Wang; P Beaune; L S Kaminsky; G A Dannan; F F Kadlubar; D Larrey; F P Guengerich
Journal:  Biochemistry       Date:  1983-11-08       Impact factor: 3.162

Review 8.  Clinical pharmacokinetics of oral anticoagulants.

Authors:  J G Kelly; K O'Malley
Journal:  Clin Pharmacokinet       Date:  1979 Jan-Feb       Impact factor: 6.447

9.  A study of the interaction of omeprazole and warfarin in anticoagulated patients.

Authors:  P Unge; L E Svedberg; A Nordgren; H Blom; T Andersson; P O Lagerström; J P Idström
Journal:  Br J Clin Pharmacol       Date:  1992-12       Impact factor: 4.335

10.  Identification and characterization of the cytochrome P450 enzymes involved in N-dealkylation of propafenone: molecular base for interaction potential and variable disposition of active metabolites.

Authors:  S Botsch; J C Gautier; P Beaune; M Eichelbaum; H K Kroemer
Journal:  Mol Pharmacol       Date:  1993-01       Impact factor: 4.436

View more
  17 in total

1.  A pharmacokinetic-pharmacodynamic model for predicting the impact of CYP2C9 and VKORC1 polymorphisms on fluindione and acenocoumarol during induction therapy.

Authors:  Céline Verstuyft; Xavier Delavenne; Alexandra Rousseau; Annie Robert; Michel Tod; Bertrand Diquet; Martine Lebot; Patrice Jaillon; Laurent Becquemont
Journal:  Clin Pharmacokinet       Date:  2012-01-01       Impact factor: 6.447

2.  Rofecoxib interaction with oral anticoagulant acenocoumarol.

Authors:  François Girardin; Michèle Siegenthaler; Philippe De Moerloose; Jules Desmeules
Journal:  Eur J Clin Pharmacol       Date:  2003-07-25       Impact factor: 2.953

Review 3.  Effects of the antifungal agents on oxidative drug metabolism: clinical relevance.

Authors:  K Venkatakrishnan; L L von Moltke; D J Greenblatt
Journal:  Clin Pharmacokinet       Date:  2000-02       Impact factor: 6.447

Review 4.  Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol.

Authors:  Mike Ufer
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

5.  Prediction of the effects of genetic polymorphism on the pharmacokinetics of CYP2C9 substrates from in vitro data.

Authors:  Makiko Kusama; Kazuya Maeda; Koji Chiba; Akinori Aoyama; Yuichi Sugiyama
Journal:  Pharm Res       Date:  2008-12-12       Impact factor: 4.200

6.  Increased frequency of CYP2C9 variant alleles and homozygous VKORC1*2B carriers in warfarin-treated patients with excessive INR response.

Authors:  Espen Molden; Cecilie Okkenhaug; Erik Ekker Solberg
Journal:  Eur J Clin Pharmacol       Date:  2010-03-31       Impact factor: 2.953

7.  Role of human liver microsomal CYP2C9 in the biotransformation of lornoxicam.

Authors:  P Bonnabry; T Leemann; P Dayer
Journal:  Eur J Clin Pharmacol       Date:  1996       Impact factor: 2.953

Review 8.  Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions.

Authors:  R J Bertz; G R Granneman
Journal:  Clin Pharmacokinet       Date:  1997-03       Impact factor: 6.447

Review 9.  Pharmacogenetics of oral anticoagulants: a basis for dose individualization.

Authors:  Simone Stehle; Julia Kirchheiner; Andreas Lazar; Uwe Fuhr
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

10.  Pharmacokinetic drug-drug interaction of the novel anticancer agent E7070 and acenocoumarol.

Authors:  H J G Desirée van den Bongard; Rolf W Sparidans; David J P Critchley; Jos H Beijnen; Jan H M Schellens
Journal:  Invest New Drugs       Date:  2004-04       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.